ICON Public Limited Company
ICLRHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company carries a $10.53B market cap, placing it firmly in the large-cap category. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Market Cap
$10.53B
Beta
1.23
P/E (TTM)
47.43
P/E (Fwd)
11.69
EPS (TTM)
$2.90
EPS (Fwd)
$11.76
ROE
2.5%
ROA
3.9%
Cash
$647.3M
Total Debt
$3.56B
Free CF
$769.3M
52W Change
-1.5%
Annual Financials
Cash vs Debt
On the balance sheet, ICLR has $647.3M in cash with $3.56B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $769.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 2.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.9% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $7.74B (2022) to $8.25B (2025).
ICON Public Limited Company carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing ICLR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.